Day: January 5, 2022

Presentation scheduled for Monday January 10, 2022 at 9:45 AM ET NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday January 10, 2022 at 9:45 AM ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG’s website following the event. ABOUT TG THERAPEUTICS, INC.TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel...

Phase III study to include a new primary endpoint, the modified HiSCR New primary endpoint and Phase III trial design to be discussed in detail at virtual R&D event on February 3rd Phase III program to focus on HS patients with active draining tunnels and will start enrolling patients in Q2JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the initiation of the Phase III program with vilobelimab in hidradenitis suppurativa (HS) patients with active draining tunnels. The new primary endpoint, called modified HiSCR (Hidradenitis Suppurativa Clinical Response), as suggested by the FDA, will include measuring the reduction of all three types of lesions – inflammatory...

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that the company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2022. Presentation DetailsDate: Wednesday, Jan. 12, 2022Time: 8:15-8:55 a.m. ET A live webcast of the company presentation and Q&A session will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation BioGeneration Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform...

TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s Co-Founder and CEO, Joseph del Moral, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13, 2022. A recording of Field Trip’s presentation will be available on-demand from Monday, January 10th at 7:00a.m. Eastern Time, through the following link: https://journey.ct.events/view/e1c372f0-cdc4-4d16-9e54-8508bd642c8d. The webcast recording will also be accessible on Field Trip’s investor relations website and via the above link for 90 days. Institutional investors interested in scheduling...

— Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune diseases — — Kyverna to lead and fund preclinical and clinical development; Intellia to receive option to co-develop and co-promote with lead U.S. commercialization rights — CAMBRIDGE, Mass. and EMERYVILLE, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, and Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases, today announced a licensing and collaboration agreement for the development of an allogeneic CD19...

TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) — RAMM Pharma Corp., including its wholly owned subsidiaries, the “Company” or “RAMM”) (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical products, applauds France’s new regulatory framework for the sale of cannabidiol (“CBD”). Pursuant to the recent announcement, France will allow the utilization of the whole hemp plant, including flowers and leaves, for the industrial production of extracts by setting the THC limit to 0.3% in both bulk extracts and final products, without any limitation for other cannabinoids. The French Health Ministry’s ordinance, published on Friday 31 December, 2021 in the Journal Officiel, provides a new regulatory framework for the sale and trading of hemp extracts. The ordinance is published at the following link: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000044793213. Further...

Guy Davis Joins as Senior Managing Director, JP Eldred Joins as Managing Director WASHINGTON, Jan. 05, 2022 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Guy Davis as a Senior Managing Director and JP Eldred as a Managing Director within the Corporate Finance & Restructuring segment. Mr. Davis and Mr. Eldred, who are based in Richmond, Va., lead a team of eight other professionals who advise companies prior to and throughout the restructuring process, including bankruptcy planning, execution, plan confirmation and post-emergence operations. They have substantial experience providing litigation support and expert testimony in a range of matters such as breach of contract, lost profits, business interruption damages, valuation, fraudulent conveyance, solvency and employment. In addition...